Pittsburgh Business Times- UPMC Enterprises, the medical technology investment arm of UPMC, has purchased interest in RxAnte, a company that uses analytics to predict how patients will adhere to the medications they’re prescribed.
RxAnte will continue to operate as an independent company, and the investment from UPMC Enterprises will allow it to expand its offerings for Medicare, Medicaid and commercial populations, and to extend its predictive models and workflow tools to high-cost specialty drugs.
Recent Posts
A (Dog’s) Day in the Life at UPMC Enterprises
I’m a simple man; I need food, water, treats, and enough stimulation and hard work …
Read More →
The Benefits of Retrospectives
Across the world, Agile teams use retrospectives (‘retros’) to look back and discuss their progress …
Read More →